-
-
-
-
-
-
-
Spero Therapeutics (SPRO) Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline
-
-
-
-
-
-
-
Spero Therapeutics (SPRO) Granted FDA Priority Review of NDA for Tebipenem HBr
-
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

